vol. 5 6/2016 Inżynier i Fizyk Medyczny
348
artykuł
\
article
medycyna nuklearna
\
nuclear medicine
a parametric method using FDG-PET/CT images in patients with
oesophageal cancer
, EJNMMI Res., 4, 2014, 12.
29.
A. Samuel:
PET/CT in pediatric oncology
, Indian J Cancer, 47(4),
2010, 360.
30.
T.J. Janus, E.E. Kim, R. Tilbury, J.M. Bruner, W.K. Yung:
Use of
[18F]fluorodeoxyglucose positron emission tomography in patients
with primary malignant brain tumors
, Ann Neurol., 33(5), 1993,
540-548.
31.
W. van Elmpt, M. Öllers, P. Lambin, D. De Ruysscher:
Repeated
PET/CT Imaging in NSCLC: The Impact of Volumetric Changes and
Baseline Shifts of the Tumor on the Radiotherapy Plan Quality
, Int
J Radiat Oncol., 78(3), 2010, 531-532.
32.
M. D’souza, A. Jaimini, A. Bansal, M. Tripathi, R. Sharma, A. Mon-
dal et al.:
FDG-PET/CT in lymphoma
, Indian J Radiol Imaging,
23(4), 2013, 354.
33.
K.H. Seol, J.E. Lee:
PET/CT planning during chemoradiotherapy
for esophageal cancer
, Radiat Oncol J., 32(1), 2014, 31.
34.
E. Ozkan, M. Araz, C. Soydal, O.N. Kucuk:
The role of 18F-FDG-
-PET/CT in the preoperative staging and posttherapy follow up of
gastriccancer: Comparison with spiral CT
, World J Surg Oncol.,
9(1), 2011, 75.
35.
A. Cinar, E.A. Gencoglu, M. Korkmaz:
Restaging colorectal cancer
and PET/CT
, Turkish J Surg., 29(2), 2013, 75-80.
36.
V. Paidpally, A. Chirindel, S. Lam, N. Agrawal, H. Quon, RM.
Subramaniam:
FDG-PET/CT imaging biomarkers in head and neck
squamous cell carcinoma
, Imaging Med., 4(6), 2012, 633-647.
37.
E. Tatci, O. Ozmen, Y. Dadali, I.U. Biner, A. Gokcek, F. Demirag
et al.:
The role of FDG PET/CT in evaluation of mediastinal masses
and neurogenic tumors of chest wall
, Int J Clin Exp Med., 8(7),
2015, 11146-11152.
38.
B. Mittal, R. Sen, A. Bhattacharya, K. Manohar:
Recurrent giant
cell tumor of foot detected by F18-FDG PET/CT
, Indian J Nucl
Med., 27(4), 2012, 262.
39.
R. Cabañas:
An Approach for the Treatment of Penile
, Cancer, 39,
1977, 456-466.
40.
B.J.E. Gershenwald, W. Thompson, P.F. Mansfield, J.E. Lee, M.I.
Colome, C. Tseng et al.: Multi-Institutional Melanoma Lym-
phatic Mapping Experience: The Prognostic Value of Sentinel
Lymph Node Status in 612 StageIor II Melanoma Patient, 17(3),
1999, 976-983.
41.
R.A. Valdés Olmos, S. Vidal-Sicart, O.E. Nieweg:
SPECT-CT and
real-time intraoperative imaging: New tools for sentinel node loca-
lization and radioguided surgery?
, Eur J Nucl Med Mol Imaging,
36(1), 2009, 1-5.
42.
Z. Nogareda, A. Álvarez, P. Perlaza, F.X. Caparrós, I. Alonso,
P. Paredes et al.:
Presence of intramammary lymph nodes in the
preoperative lymphoscintigraphy to locate the sentinel lymph
node. Clinical significance
, Rev Española Med Nucl e Imagen Mol,
(English Ed. SEMNIM), 34(2), 2015, 83-88.
43.
S. Vidal-Sicart, F. Giammarile, G. Mariani, R.A. Valdés Olmos:
Pre- and intra-operative imaging techniques for sentinel node loca-
lization in breast cancer
, Imaging Med., 5(3), 2013, 275-291.
44.
A. Hubalewska-Dydejczyk, J. Kulig, P. Szybiński, R. Mikołajczak,
D. Pach, A. Sowa-Staszczak et al.:
Radio-guided surgery with the
use of [99mTc-EDDA/HYNIC] octreotate in intra-operative detec-
tion of neuroendocrine tumours of the gastrointestinal tract
, Eur
J Nucl Med Mol Imaging, 34(10), 2007, 1545-1555.
45.
K. Zukotynski, F. Fahey, H. Jadvar, J. Capala:
Targeted Radionuc-
lide Therapy: Practical Applications and Future Prospects
, Biomark
Cancer, 8(1), 2016, 35.
46.
J.-P. Pouget, C. Lozza, E. Deshayes, V. Boudousq, I. Navarro-
-Teulon:
Introduction to radiobiology of targeted radionuclide the-
rapy
, Front Med., 2, 2015, 12.
47.
C. Bodet-Milin:
Radioimmunotherapy of B-cell non-Hodgkin’s lym-
phoma
, Front Oncol., 3, 2013, 1-13.
48.
D. Ersahin, I. Doddamane, D. Cheng:
Targeted radionuclide thera-
py
, Cancers (Basel), 3(4), 2011, 3838-3855.
49.
I. Tannock, M. Gospodarowicz, W. Meakin, T. Panzarella, L. Ste-
wart, W. Rider:
Treatment of metastatic prostatic cancer with low-
-dose prednisone: evaluation of pain and quality of life as pragma-
tic indices of response
, J Clin Oncol., 7(5), 1989, 590-597.
50.
G.D. Roodman:
Mechanisms of bone lesions in multiple myeloma
and lymphoma
, Cancer, 80(8), 1997, 1557-1563.
51.
M. Tomblyn:
The Role of Bone-Seeking Radionuclides in the Pal-
liative Treatment of Patients With Painful Osteoblastic Skeletal
Metastases
, Cancer Control., 19(2), 2012, 137-144.
52.
M. Fischer, W.U. Kampen:
Radionuclide Therapy of Bone Metasta-
ses
, Breast Care, 7(2), 2012, 100-107.
53.
J. Goyal, E.S. Antonarakis:
Bone-targeting radiopharmaceuticals
for the treatment of prostate cancer with bone metastases
, Cancer
Lett., 323(2), 2012, 135-146.
54.
V. Rufini, M.L. Calcagni, R.P. Baum:
Imaging of Neuroendocrine
Tumors
, Semin Nucl Med, 36(3), 2006, 228-247.
55.
A. Otte, S. Dellas, E.U. Nitzsche, R. Herrmann:
Yttrium-90 la-
belled somatostatin-analogue for cancer treatment
, Lancet,
351(9100), 1998, 417-418.
56.
O.C. Boerman, W.J.G. Oyen, F.H.M. Corstens:
Radio-labeled re-
ceptor-binding peptides: A new class of radiopharmaceuticals
, Se-
min Nucl Med., 30(3), 2000, 195-208.
57.
E. García-Garayoa, P. Bläuenstein, A. Blanc, V. Maes, D. Tourwé,
P.A. Schubiger:
A stable neurotensin-based radiopharmaceutical
for targeted imaging and therapy of neurotensin receptor-positive
tumours
, Eur J Nucl Med Mol Imaging, 36(1), 2009, 37-47.
58.
D.A. Mulford, D.A. Scheinberg, J.G. Jurcic:
The promise of targe-
ted {alpha}-particle therapy
, J Nucl Med., 46(1), 2005, 199-204.
59.
Y. Dekempeneer, M. Keyaerts, A. Krasniqi, J. Puttemans, S.
Muyldermans, T. Lahoutte et al.:
Targeted alpha therapy using
short-lived alpha-particles and the promise of nanobodies as tar-
geting vehicle
, Expert Opin Biol Ther., 16(8), 2016, 1035-1047.
60.
Å.M. Ballangrud, W.H. Yang, S. Palm, R. Enmon, P.E. Borchardt,
V.A. Pellegrini et al.:
Alpha-particle emitting atomic generator
(actinium-225)-labeled trastuzumab (Herceptin) targeting of bre-
ast cancer spheroids: Efficacy versus HER2/neu expression
, Clin
Cancer Res., 10(13), 2004, 4489-4497.
61.
G.-J. Beyer, M. Miederer, S. Vranjes-Durić, J.J. Comor, G. Künzi,
O. Hartley et al.:
Targeted alpha therapy in vivo: direct evidence for
single cancer cell kill using 149Tb-rituximab
, Eur J Nucl Med Mol
Imaging, 31(4), 2004, 547-554.
62.
J. Dahle, T.J. Jonasdottir, H. Heyerdahl, J.M. Nesland, J. Borre-
bæk, A.K. Hjelmerud et al.:
Assessment of long-term radiotoxicity
after treatment with the low-dose-rate alpha-particle-emitting
radioimmunoconjugate 227Th- rituximab
, Eur J Nucl Med Mol
Imaging, 37(1), 2010, 93-102.
63.
M. Miederer, D.A. Scheinberg, M.R. McDevitt:
Realizing the
potential of the Actinium-225 radionuclide generator in targeted
alpha particle therapy applications
, Adv Drug Deliv Rev., 60(12),
2008, 1371-1382.
64.
M.R. McDevitt:
Tumor Therapy with Targeted Atomic Nanogene-
rators
, Science, 294(5546), 2001, 1537-1540.
65.
D. Milenic, K. Garmestani, E. Dadachova, L. Chappell, P. Albert,
D. Hill et al.:
Radioimmunotherapy of human colon carcinoma
xenografts using a 213Bi-labeled domain-deleted humanized mo-
noclonal antibody
, Cancer Biother Radiopharm, 19(2), 2004,
135-147.
66.
S. Palm, T. Bäck, I. Claesson, A. Danielsson, J. Elgqvist, S. Frost
et al.:
Therapeutic Efficacy of Astatine-211-Labeled Trastuzumab
on Radioresistant SKOV-3 Tumors in Nude Mice
, Int J Radiat Oncol
Biol Phys., 69(2), 2007, 572-579.
67.
C. Raja, P. Graham, S.M. Abbas Rizvi, E. Song, H. Goldsmith, J.
Thompson et al.:
Interim analysis of toxicity and response in phase
1 trial of systemic targeted alpha therapy for metastatic melano-
ma
, Cancer Biol Ther., 6(6), 2007, 846-852.
68.
M. Miederer, G. Henriksen, A. Alke, I. Mossbrugger, L. Quintanil-
la-Martinez, R. Senekowitsch-Schmidtke et al.:
Preclinical eva-
luation of the
α-
particle generator nuclide 225Ac for somatosta-
tin receptor radiotherapy of neuroendocrine tumors
, Clin Cancer
Res., 14(11), 2008, 3555-3561.
69.
E. Drecoll, F.C. Gaertner, M. Miederer, B. Blechert, M. Vallon,
J.M. Müller et al.:
Treatment of peritoneal carcinomatosis by tar-
geted delivery of the radio-labeled tumor homing peptide 213Bi-D-
TPA-[F3]2 into the nucleus of tumor cells
, PLoS One, 4(5), 2009.
70.
M.T. Truong, N. Kovalchuk:
Radiotherapy planning
, PET Clin.,
10(2), 2015, 279-296.
71.
I. Verel, G.W. Visser, R. Boellaard, M.S.-V. Walsum, G.B. Snow
et al.:
89 Zr Immuno-PET: Comprehensive Procedures for the Pro-
duction of 89 Zr-Labeled Monoclonal Antibodies
, J Nucl Med.,
44, 2003, 1271-1281.
72.
B. Pirotte, S. Goldman, N. Massager, P. David, D. Wikler, A. Van-
desteene et al.:
Comparison of 18F-FDG and 11C-methionine for
PET-guided stereotactic brain biopsy of gliomas
, J Nucl Med.,
45(8), 2004, 1293-1298.
73.
D. Pauleit, F. Floeth, K. Hamacher, M.J. Riemenschneider,
G. Reifenberger, H.W. Müller et al.:
O-(2-[18F]fluoroethyl)-L-ty-
rosine PET combined with MRI improves the diagnostic assessment
of cerebral gliomas
, Brain, 128(3), 2005, 678-687.
